{ "meta": { "data_length": 1, "message": "Statements retrieved successfully", "request_url": "http://api.moalmanac.org/statements?agent_id=agent%3Aorg%3Afda&proposition_id=prop%3Avtxr%3A119", "status": "success", "status_code": 200, "timestamp_elapsed": 0.004149, "timestamp_received": "2026-09-25T00:13:54.162762+00:00Z", "timestamp_returned": "2026-09-25T00:13:54.166911+00:00Z", "trace_id": "f81c16b3-53aa-4264-9214-ba7a1706de48" }, "service": { "github": "https://github.com/vanallenlab/moalmanac-db", "name": "Molecular Oncology Almanac", "license": "GPL-2.0", "release": "draft", "url": "https://dev.moalmanac.org", "last_updated": "2026-08-02" }, "data": [ { "id": "stmt:fda:idhifa:0:8", "type": "Statement", "description": "The U.S. Food and Drug Administration granted approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-30:0", "type": "Contribution", "description": "Initial access of FDA approvals", "date": "2024-10-30", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:fda:2017-08-01:0", "type": "Contribution", "description": "Indication received traditional approval.", "date": "2017-08-01", "contributor": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." } } ], "reportedIn": [ { "id": "doc:fda:idhifa", "type": "Document", "documentType": "Regulatory approval", "name": "Idhifa (enasidenib) [package insert]. FDA.", "title": null, "aliases": [], "description": "Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf. Revised December 2023. Accessed October 30, 2024.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209606" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." }, "description": "The organization that published this document." }, { "name": "company", "value": "Celgene Corporation.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Idhifa", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "enasidenib", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": null, "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 209606, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2023-12-21", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "proposition": { "id": "prop:vtxr:119", "type": "VariantTherapeuticResponseProposition", "predicate": "predictsSensitivityTo", "subjectVariant": { "type": "CategoricalVariant", "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition." }, "conditionQualifier": { "id": "dis:oncotree:AML", "conceptType": "Disease", "name": "Acute Myeloid Leukemia", "mappings": [], "extensions": [ { "name": "solid_tumor", "value": false, "description": "Boolean value for if this tumor type is categorized as a solid tumor." } ], "primaryCoding": { "id": "coding:oncotree:AML", "code": "AML", "name": "Acute Myeloid Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": [ "https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML" ] } }, "objectTherapeutic": { "id": "tx:ncit:C111573", "conceptType": "Therapy", "name": "Enasidenib", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:1940332", "code": "1940332", "name": "enasidenib", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1940332" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:793797", "code": "793797", "name": "enasidenib", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/793797" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:sctid:763038001", "code": "763038001", "name": "Enasidenib", "system": "SNOMED", "systemVersion": "2025-03-01", "iris": [ "https://browser.ihtsdotools.org/?perspective=full&conceptId1=763038001&edition=MAIN/2025-03-01&release=&languages=en" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:35621786", "code": "35621786", "name": "Enasidenib", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/35621786" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "IDH2 inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C111573", "code": "C111573", "name": "Enasidenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C111573" ] } }, "extensions": [ { "name": "biomarkers", "value": [ { "id": "bmkr.criterion:115", "present": true, "subject": { "id": "bmkr:115", "type": "CategoricalVariant", "name": "IDH2 p.R172W", "constraints": [ { "type": "DefiningAlleleConstraint", "allele": { "id": "ga4gh:VA.yoh4PZ0RvxllKuUUhI-kHp7KqeykbEFP", "type": "Allele", "name": "NP_002159.2:p.Arg172Trp", "aliases": [ "NP_002159.2:p.R172W", "IDH2 p.R172W" ], "description": "VRS variation of NP_002159.2:p.Arg172Trp", "digest": "yoh4PZ0RvxllKuUUhI-kHp7KqeykbEFP", "expressions": [ { "syntax": "hgvs.p", "value": "NP_002159.2:p.Arg172Trp", "extensions": [ { "name": "hgvs.p_short", "value": "p.R172W" } ] } ], "location": { "id": "ga4gh:SL.UuG3IrLVJV7S2Qjtt99SWVQuiYDLlHxa", "type": "SequenceLocation", "name": null, "aliases": [], "description": "Amino acid position 172 of the Refseq protein NP_002159.2, which is the protein product of the MANE Select coding transcript for IDH2 (refseq:NM_002168.4).", "digest": "UuG3IrLVJV7S2Qjtt99SWVQuiYDLlHxa", "sequenceReference": { "id": "ga4gh:SQ.xop1Mrzn5Llu7Dj-BULoAd8Xmlbs-l-y", "type": "SequenceReference", "name": "NP_002159.2", "aliases": [ "ensembl:ENSP00000331897.3", "ga4gh:SQ.xop1Mrzn5Llu7Dj-BULoAd8Xmlbs-l-y", "refseq:NP_002159.2" ], "description": "The protein product of the MANE Select coding transcript for IDH2 (refseq:NM_002168.4), corresponding to the Refseq protein accession NP_002159.2.", "moleculeType": "protein", "refgetAccession": "SQ.xop1Mrzn5Llu7Dj-BULoAd8Xmlbs-l-y", "residueAlphabet": "aa" }, "start": 171, "end": 172, "sequence": "R" }, "state": { "type": "LiteralSequenceExpression", "sequence": "W" } }, "relations": [] }, { "type": "FeatureContextConstraint", "featureContext": { "id": "gene:hgnc:5383", "conceptType": "Gene", "name": "IDH2", "primaryCoding": { "id": "coding:hgnc:5383", "code": "HGNC:5383", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5383" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000182054", "code": "ENSG00000182054", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000182054" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:3418", "code": "3418", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/3418" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_002168.4", "code": "NM_002168.4", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_002168.4" ] } } ] } } ], "extensions": [ { "name": "biomarker_type", "value": "Somatic variant" }, { "name": "chromosome", "value": "15" }, { "name": "start_position", "value": 90631839 }, { "name": "end_position", "value": 90631839 }, { "name": "reference_allele", "value": "T" }, { "name": "alternate_allele", "value": "A" }, { "name": "cdna_change", "value": "c.514A>T" }, { "name": "protein_change", "value": "p.R172W" }, { "name": "variant_annotation", "value": "Missense" }, { "name": "exon", "value": 4 }, { "name": "rsid", "value": "rs1057519906" }, { "name": "hgvsg", "value": "15:g.90631839T>A" }, { "name": "hgvsc", "value": "ENST00000330062.3:c.514A>T" } ] } } ], "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic." } ] }, "strength": { "id": "str:ncit:C25425", "conceptType": "Evidence", "name": "Approval", "mappings": [], "primaryCoding": { "id": "coding:ncit:C25425", "code": "C25425", "name": "Approval", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425" ] } }, "extensions": [ { "name": "status", "value": "Active", "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db." }, { "name": "indication", "value": { "id": "ind:fda:idhifa:0", "type": "Indication", "description": "IDHIFA is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-30:0", "type": "Contribution", "description": "Initial access of FDA approvals", "date": "2024-10-30", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:fda:2017-08-01:0", "type": "Contribution", "description": "Indication received traditional approval.", "date": "2017-08-01", "contributor": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." } } ], "reportedIn": [ { "id": "doc:fda:idhifa", "type": "Document", "documentType": "Regulatory approval", "name": "Idhifa (enasidenib) [package insert]. FDA.", "title": null, "aliases": [], "description": "Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf. Revised December 2023. Accessed October 30, 2024.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209606" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." }, "description": "The organization that published this document." }, { "name": "company", "value": "Celgene Corporation.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Idhifa", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "enasidenib", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": null, "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 209606, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2023-12-21", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "extensions": [ { "name": "status", "value": "Approved", "description": "Current approval status." } ] }, "description": "The underlying Indication supporting this Statement." } ] } ] }